RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $265
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi maintains an Outperform rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $250 to $265.
June 27, 2024 | 2:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reaffirmed its Outperform rating on Alnylam Pharmaceuticals and increased the price target from $250 to $265, indicating confidence in the company's future performance.
The increase in the price target from $250 to $265 by RBC Capital suggests a positive outlook for Alnylam Pharmaceuticals. The reaffirmation of the Outperform rating indicates that the analyst expects the stock to perform well relative to the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100